Bacteriophage sales will expand through 2036, with phage therapeutics holding a 72% share of the product type segment in 2026. The market is expected to reach USD 57.2 million in 2026 and USD 128.2 million by 2036, creating an absolute opportunity of USD 71 million between 2026 and 2036.